Amgen Inc. (NASDAQ:AMGN) Shares Sold by Bard Financial Services Inc.

Bard Financial Services Inc. lessened its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 43.7% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 28,185 shares of the medical research company’s stock after selling 21,905 shares during the quarter. Amgen accounts for about 1.1% of Bard Financial Services Inc.’s holdings, making the stock its 27th biggest position. Bard Financial Services Inc.’s holdings in Amgen were worth $9,081,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of AMGN. Lantz Financial LLC raised its holdings in Amgen by 5.1% during the 2nd quarter. Lantz Financial LLC now owns 1,779 shares of the medical research company’s stock worth $556,000 after buying an additional 87 shares during the period. Great Valley Advisor Group Inc. increased its holdings in shares of Amgen by 9.7% in the 2nd quarter. Great Valley Advisor Group Inc. now owns 7,772 shares of the medical research company’s stock valued at $2,429,000 after purchasing an additional 686 shares during the period. Baader Bank Aktiengesellschaft increased its holdings in shares of Amgen by 97.1% in the 2nd quarter. Baader Bank Aktiengesellschaft now owns 1,577 shares of the medical research company’s stock valued at $492,000 after purchasing an additional 777 shares during the period. DB Fitzpatrick & Co Inc increased its holdings in shares of Amgen by 145.4% in the 2nd quarter. DB Fitzpatrick & Co Inc now owns 4,311 shares of the medical research company’s stock valued at $1,347,000 after purchasing an additional 2,554 shares during the period. Finally, Corundum Group Inc. increased its holdings in shares of Amgen by 111.2% in the 2nd quarter. Corundum Group Inc. now owns 4,113 shares of the medical research company’s stock valued at $1,285,000 after purchasing an additional 2,166 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Down 0.3 %

AMGN opened at $275.05 on Wednesday. Amgen Inc. has a 1-year low of $257.80 and a 1-year high of $346.85. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The stock has a market capitalization of $147.85 billion, a price-to-earnings ratio of 35.31, a P/E/G ratio of 3.02 and a beta of 0.55. The business has a 50 day moving average of $305.69 and a 200-day moving average of $315.66.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating the consensus estimate of $5.11 by $0.47. The company had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. Amgen’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period in the prior year, the business earned $4.96 earnings per share. As a group, sell-side analysts anticipate that Amgen Inc. will post 19.51 earnings per share for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.46%. This is a positive change from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio is presently 115.24%.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on AMGN shares. StockNews.com upgraded Amgen from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Barclays upped their target price on Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a report on Monday, October 7th. Truist Financial cut Amgen from a “buy” rating to a “hold” rating and boosted their price target for the company from $320.00 to $333.00 in a research note on Monday, October 14th. Cantor Fitzgerald reissued an “overweight” rating and issued a $405.00 price target on shares of Amgen in a research note on Tuesday, October 22nd. Finally, Bank of America reissued an “underperform” rating and issued a $256.00 price target on shares of Amgen in a research note on Tuesday. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Amgen presently has an average rating of “Hold” and a consensus price target of $319.68.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.